influenza
virus
iav
lead
caus
sever
respiratori
diseas
death
iav
pose
threat
particularli
human
health
continu
emerg
season
epidem
occasion
global
pandem
krammer
et
al
paul
subbarao
epidemiolog
success
iav
depend
abil
effici
infect
subsequ
transmit
among
host
individu
typic
via
airborn
respiratori
droplet
killingley
nguyen
vantam
neumann
kawaoka
combat
danger
signific
resourc
deploy
establish
global
network
detect
sequenc
surveil
potenti
hazard
iav
strain
within
human
speci
ziegler
et
al
human
iav
compris
three
strain
introduc
popul
avian
swine
speci
pandem
outbreak
last
centuri
garten
et
al
smith
et
al
webster
et
al
hemagglutinin
human
iav
bind
specif
nacetylneuramin
acid
sialic
acid
link
galactos
present
human
upper
airway
cell
avian
iav
strain
preferenti
recogn
sialosid
connor
et
al
diverg
receptor
structur
andor
chemistri
form
protect
speci
barrier
prevent
transmiss
circul
avian
iav
subtyp
within
human
without
adapt
humantyp
receptor
de
graaf
fouchier
imai
kawaoka
avian
viru
progenitor
respons
pandem
requir
oneor
twoamino
acid
mutat
receptorbind
site
rb
achiev
switch
avian
humantyp
receptor
specif
connor
et
al
tumpey
et
al
addit
wellstudi
specif
chang
human
shown
acquir
adapt
includ
increas
thermal
stabil
decreas
fusionph
increas
nlink
glycosyl
linster
et
al
zhang
et
al
mani
chang
reflect
escap
immun
respons
repres
adapt
alter
improv
bind
infect
replic
human
cell
role
addit
glycan
particularli
detail
composit
structur
remain
compar
underinvestig
inde
two
recent
literatur
exampl
report
sitespecif
quantit
analysi
nlink
glycan
repres
influenza
provid
limit
inform
regard
impact
speci
origin
evolut
passag
human
khatri
et
al
parson
et
al
report
comprehens
sitespecif
analysi
nlink
glycan
contemporari
iav
compris
six
evolutionarili
distinct
hemagglutinin
subtyp
human
avian
influenza
virus
find
ha
stemdomain
glycosit
conserv
across
subtyp
exhibit
extens
process
glycan
highmannos
complextyp
glycosit
within
head
domain
human
includ
ad
increment
time
exhibit
signific
oligomannosetyp
glycan
minim
process
consist
presenc
conserv
oligomannos
glycan
influenza
show
even
present
low
frequenc
highmannosespecif
lectin
galanthu
nivali
gnl
snowdrop
lectin
kaku
goldstein
use
univers
label
detect
whole
iav
recombin
sialosid
microarray
without
requir
specif
antivir
reagent
monoclon
antibodi
antisera
moreov
gnl
also
abl
inhibit
receptor
bind
broadli
neutral
recent
human
virus
either
compar
superior
potenc
panel
antivir
antibodi
energyminim
model
glycosyl
crystal
structur
six
repres
reveal
conserv
posit
type
glycan
individu
glycosyl
site
particularli
within
group
ha
phylogenet
class
air
nobusawa
et
al
comparison
glycosyl
suggest
overal
locat
ha
togeth
local
structur
featur
surround
glycosit
major
determin
oligomannos
glycoform
rather
dens
pack
multipl
site
observ
virus
human
immunodefici
viru
hiv
cao
et
al
cao
et
al
structur
map
highmannos
glycosit
ha
human
virus
reveal
presenc
small
highmannos
patch
close
proxim
rb
top
account
effect
gnl
neutral
insight
immun
recognit
glycosyl
vaccin
product
develop
univers
viru
detect
via
surfac
glycan
discuss
light
find
influenza
divers
subtyp
exhibit
substanti
differ
nlink
glycan
process
investig
differ
iav
glycosyl
perform
global
sitespecif
analysi
glycan
occup
degre
process
highmannos
complextyp
glycan
potenti
nlink
glycosyl
site
present
six
repres
ha
ectodomain
human
avian
iav
includ
human
pandem
human
season
aviet
nam
avian
origin
avian
origin
avian
origin
ajiangxi
avian
origin
strain
select
includ
two
contemporari
human
iav
strain
four
avian
iav
togeth
compris
two
major
ha
phylogenet
subgroup
group
group
proteomicsbas
method
sitespecif
analysi
nlink
glycan
process
use
endoglycosidas
introduc
mass
signatur
contain
either
glycan
minim
process
highmannos
hybridtyp
extens
process
complextyp
nglycan
allow
semiquantit
assess
proport
glycoform
present
glycosit
cao
et
al
cao
et
al
result
reveal
differ
glycosyl
individu
particularli
human
avian
iav
figur
human
shown
glycosyl
statu
ha
nlink
glycosit
asnxthrser
either
complex
type
purpl
highmannos
hybrid
type
green
glycan
gray
individu
posit
within
b
c
e
f
bar
distribut
along
x
axi
accord
rel
posit
primari
sequenc
specif
glycosit
depict
number
glycosyl
asparagin
n
two
glycosit
correspond
glycopeptid
could
detect
ms
analysi
shown
open
gray
bar
glycosit
posit
exclud
due
protein
stabil
construct
includ
fold
ectodomain
residu
histogram
depict
averag
occup
error
bar
show
standard
error
figur
exhibit
larg
proport
highmannos
type
glycan
particularli
glycosit
ha
head
domain
also
contain
rb
convers
major
glycosit
present
avianderiv
uniformli
process
complextyp
glycan
figur
interestingli
although
contemporari
human
regard
highli
glycosyl
potenti
glycosit
observ
one
posit
entir
unoccupi
two
site
occupi
glycan
less
suggest
averag
modest
fulli
occupi
glycosit
line
recent
propos
ha
glycan
satur
limit
altman
et
al
sever
poorli
occupi
glycosit
singl
unoccupi
site
number
use
throughout
fall
close
proxim
glycosit
primari
amino
acid
sequenc
figur
similarli
adjac
glycosit
posit
appear
result
minim
process
least
one
glycosit
pair
observ
oligomannosetyp
figur
notabl
howev
glycan
crowd
reason
underprocess
glycan
sinc
isol
glycosit
display
signific
proport
highmannos
glycan
figur
suggest
architectur
fold
ha
structur
may
also
influenc
extent
glycan
process
six
conserv
glycosit
predominantli
complex
type
figur
group
contain
pair
predominantli
complex
glycan
group
featur
directli
compar
pair
glycosit
posit
also
found
mostli
complex
type
figur
label
influenza
ha
although
analyz
contain
variabl
amount
highmannos
type
glycan
includ
least
low
level
oligomannos
rais
possibl
could
specif
label
mannoseselect
lectin
subsequ
use
detect
gnl
commerci
avail
nonca
depend
lectin
specif
mannosid
sugar
found
highmannos
type
nglycan
make
candid
detect
iav
glycan
array
experi
glycan
array
contain
nlink
glycan
man
glcnac
core
gnl
appear
abl
bind
complextyp
glycan
termin
sialic
acid
gave
minim
background
reactiv
sialyl
nlink
glycan
array
figur
list
array
glycan
see
data
assess
detect
purifi
iav
panel
six
human
avian
use
ms
analysi
appli
microarray
either
preincub
complex
antihi
secondari
antibodi
standard
protocol
see
star
method
direct
incub
pure
ha
trimer
microarray
surfac
follow
wash
incub
preform
complex
biotinyl
gnl
streptavidin
detect
bound
sampl
via
gnl
stain
highmannos
glycan
compar
achiev
antibodi
case
specif
pattern
bind
fingerprint
appear
qualit
match
figur
furthermor
gnl
detect
also
abl
enhanc
signal
weakerbind
glycan
presum
due
robust
stain
multipl
highmannos
glycosit
per
trimer
examin
util
gnl
serologyindepend
reagent
label
whole
iav
sampl
analyz
subset
four
virus
close
similar
recombin
ha
sampl
investig
plu
prepandem
human
season
strain
anew
despit
distinct
antigen
detect
gnl
specif
bind
array
clearli
observ
viru
sampl
figur
viru
sampl
maintain
close
match
receptor
specif
purifi
ha
counterpart
figur
nc
also
sought
compar
glycanspecif
label
serolog
method
detect
includ
antivir
mous
antibodi
sheepderiv
antisera
gnl
reproduc
receptor
specif
identifi
serolog
stain
show
mix
linkag
prefer
nglycan
appear
major
specif
minor
interact
receptor
figur
sinc
label
gnl
offer
compar
data
antibodi
antiserabas
detect
method
may
provid
simpl
futur
altern
detect
iav
glycanbind
assay
specif
antivir
reagent
avail
highmannos
glycan
iav
potenti
target
neutral
sinc
human
virus
featur
highmannos
glycan
potenti
key
posit
within
ha
head
domain
investig
abil
gnl
inhibit
receptor
bind
neutral
infect
vitro
use
cell
cultur
microneutr
mn
hemagglutin
inhibit
hai
gnl
neutral
virus
test
compar
superior
strength
best
mab
neutral
assay
figur
rel
specif
monoclon
antibodi
mab
known
mn
function
gnl
fail
protect
madindarbi
canin
kidney
mdck
cell
infect
viru
suggest
observ
highmannos
glycan
locat
distanc
rb
figur
convers
howev
gnl
show
potent
neutral
compar
control
mab
figur
indic
least
one
oligomannos
site
moreheavili
glycosyl
head
like
suitabl
posit
strong
inhibit
receptor
engag
compar
data
also
obtain
hai
assay
gnl
show
success
inhibit
comparison
gnl
panel
lectin
divers
glycan
specif
reveal
potent
neutral
confin
highmannosetarget
reagent
figur
investig
potenti
broad
neutral
virus
conduct
expand
mn
screen
five
recent
human
vaccin
strain
panel
eleven
mab
rais
three
strain
plu
gnl
figur
select
iav
includ
ahong
expect
variou
mab
clone
exhibit
neutral
mainli
strainspecif
manner
gener
favor
parent
iav
ha
rais
except
clone
fail
neutral
iav
test
figur
four
mab
weakli
neutral
two
show
similar
crossneutr
correspondingli
one
mab
show
similar
neutral
titer
suggest
share
epitop
share
two
virus
interestingli
despit
evolv
appear
show
littl
crossreact
mab
vice
versa
despit
highli
potent
neutral
speci
figur
wide
neutral
viru
reveal
mainli
weak
titer
eight
eleven
mab
test
interestingli
howev
mab
appear
give
strongest
mn
titer
viru
although
observ
titer
differ
gener
less
compar
small
within
context
assay
term
broad
neutral
none
antivir
mab
sampl
test
abl
neutral
five
strain
two
clone
neutral
four
five
virus
gener
weak
potenc
unsurprisingli
given
later
appear
evolut
like
advanc
antigen
drift
rel
weakli
neutralizedwith
share
reactiv
close
relat
mab
one
one
sampl
contrast
limit
neutral
viru
panel
mab
gnl
target
highmannos
glycan
gave
consist
strong
neutral
inde
gnl
show
neutral
activ
independ
underli
sequenc
antigen
drift
variant
five
viru
sampl
examin
mn
titer
compar
best
specif
mab
viru
figur
togeth
data
suggest
consider
specif
glycan
epitop
within
vaccin
design
method
promin
within
hiv
field
andrabi
et
al
could
enhanc
efficaci
broad
protect
especi
within
human
iav
strain
glycosit
accumul
oligomannos
speci
appear
conserv
across
ha
head
domain
highmannos
glycosit
map
antigen
domin
ha
head
domain
quantit
glycoproteom
data
figur
reveal
presenc
highmannos
type
glycosit
human
iav
strain
howev
gnl
neutral
viru
figur
impli
differ
local
highmannos
glycan
within
two
strain
better
understand
glycosyl
differ
set
look
glycosyl
data
six
figur
context
threedimension
structur
due
conform
flexibl
ha
glycan
typic
found
crystal
cryoelectron
microscopi
structur
deposit
pdb
therefor
employ
comput
approach
assign
energyminim
glycan
structur
conform
de
novo
glycosit
recombin
see
star
method
figur
shown
figur
top
side
view
six
ha
subtyp
energyminim
glycan
structur
model
glycosit
color
accord
domin
glycan
type
determin
ms
figur
predominantli
highmannos
complextyp
glycan
shown
green
purpl
respect
site
least
type
design
mix
color
orang
site
substanti
highmannos
content
green
present
locat
exclus
within
subunit
vast
major
found
adorn
antigen
domin
head
domain
contain
rb
figur
broad
similar
among
panel
mainli
confin
subgroup
eg
within
human
avian
origin
phylogenet
group
six
contain
one
mainli
complextyp
glycan
occupi
similar
conform
figur
cover
interfac
head
stem
domain
reason
conserv
glycan
ring
compos
mainli
complex
glycosit
glycan
includ
compar
pair
group
group
glycan
ring
appear
form
rel
close
shield
obstruct
access
top
stem
domain
form
core
ha
membranefus
machineri
within
figur
ring
harbor
two
predominantli
highmannos
glycosit
locat
immedi
headstem
interfac
similarli
locat
glycosit
also
predominantli
highmannos
figur
avian
complex
type
figur
although
cal
somewhat
close
primari
sequenc
suggest
hindranc
process
amannosidas
structur
analysi
suggest
region
uncrowd
figur
sequenc
structur
align
reveal
subtl
differ
around
posit
may
account
strong
diverg
attach
glycoform
figur
within
glycosit
compris
nt
glycosyl
sequon
compar
nss
figur
structur
hydrophob
methyl
group
appear
rotat
small
hydrophob
pocket
creat
side
chain
lead
rearrang
amino
acid
backbon
rel
approxim
rotat
side
chain
toward
protein
surfac
figur
final
energyminim
model
glycosyl
form
reveal
attach
glycan
lie
close
pack
ha
surfac
rather
extend
solventaccess
form
figur
like
contribut
reduc
access
process
consist
observ
highmannos
speci
posit
similar
structur
varianc
also
evid
whose
locat
within
shallow
pocket
beneath
major
part
head
domain
proxim
trimer
interfac
appear
result
similar
highmannos
glycoform
close
contact
ha
surfac
figur
glycan
ring
quit
undecor
particularli
avian
origin
figur
present
simplest
homogen
glycosyl
maintain
minim
decor
head
domain
mainli
complex
glycan
everi
observ
glycosit
figur
interestingli
glycosyl
profil
see
figur
close
match
locat
four
observ
glycosit
close
conserv
figur
howev
attach
speci
vari
strongli
interestingli
structur
posit
varianc
might
impair
mannosidas
process
rel
less
readili
observ
glycan
conform
respect
glycosyl
structur
appear
highli
similar
figur
within
group
featur
sever
match
compar
glycosit
includ
predominantli
complextyp
glycan
figur
also
contain
one
compar
posit
glycan
heterogen
occup
respect
complex
complex
figur
glycosyl
model
reveal
attach
glycoform
possess
differ
conform
point
directli
ha
surfac
open
conform
project
directli
toward
top
ha
pack
close
protein
surfac
potenti
reduc
access
process
figur
top
ha
molecul
rel
undecor
viral
subtyp
except
recent
human
virus
chamber
et
al
zost
et
al
figur
possess
complextyp
glycan
project
directli
molecul
like
antigen
adapt
also
shown
major
obstacl
receptor
bind
herfst
et
al
top
dens
cover
multipl
glycan
contain
fulli
occupi
glycosit
partial
occupi
speci
observ
figur
interestingli
complex
purpl
highmannosehybridg
green
mix
occup
orang
label
accord
protom
belong
either
b
c
see
top
view
trimer
interfac
ha
defin
broken
line
top
view
unoccupi
glycan
unobserv
glycopeptid
could
detect
glycan
posit
model
locat
rb
label
ha
bound
disaccharid
purpl
yellow
sphere
model
within
illustr
complex
highmannos
al
neuac
speci
color
scheme
accord
consortium
function
glycom
cfg
guid
mannos
galactos
respect
structur
locat
two
signific
highmannos
glycosit
analog
oligomannos
site
compar
figur
third
uniqu
site
posit
nearbi
creat
appear
highmannos
patch
figur
three
glycan
appear
close
rb
model
highmannos
glycan
lie
extrem
nearbi
appear
like
target
neutral
gnl
conserv
sinc
figur
also
provid
rational
observ
broad
neutral
within
group
model
highmannos
glycan
appear
pack
close
surfac
ha
molecul
similar
describ
togeth
data
suggest
model
wherebi
iav
particularli
associ
human
infect
select
increas
glycosyl
around
ha
head
domain
evolut
predominantli
highmannos
speci
particular
glycosit
may
control
structur
sequenc
featur
within
ha
minor
evolutionari
drift
human
season
strain
major
reassort
avian
virus
iav
pose
signific
complex
challeng
health
krammer
et
al
paul
subbarao
zoonot
iav
strain
adapt
transmiss
among
human
host
initi
chang
receptor
specif
increas
ha
stabil
replicationenhanc
polymeras
mutat
subsequ
antigen
drift
within
ha
head
addit
headdomain
glycan
research
mani
area
matur
significantli
last
decad
particularli
respect
receptor
specif
switch
chen
et
al
de
vri
et
al
de
vri
et
al
srinivasan
et
al
tzarum
et
al
yamada
et
al
detail
iav
glycosyl
evolutionari
adapt
chang
ha
glycom
remain
poorli
understood
inpart
due
substanti
technic
challeng
mean
mani
studi
employ
nonsitespecif
poorli
quantit
techniqu
interpret
glycosyl
pattern
advanc
method
prove
laborintens
extrem
lowthroughput
reveal
limit
insight
knowledg
ha
glycosyl
link
antigen
increas
interest
sinc
despit
longrun
immun
program
develop
effect
broadli
protect
iav
vaccin
remain
difficult
repres
major
research
goal
erbeld
et
al
studi
demonstr
variabl
heterogen
glycosyl
pattern
within
divers
panel
rang
minor
highmannos
fraction
avian
ha
stem
domain
nearcomplet
oligomannos
site
within
head
human
iav
glycoproteom
analysi
structur
glycosyl
highlight
broad
conserv
locat
mani
ha
glycan
occup
site
either
complex
highmannos
glycoform
appear
far
divers
particularli
avian
human
exampl
highli
occupi
oligomannos
site
almost
exclus
associ
humanadapt
suggest
possibl
reduc
glycan
process
might
select
part
host
adapt
notabl
glycosit
signific
oligomannos
content
wellconserv
sinc
respect
emerg
iav
human
figur
glycoproteom
analysi
two
earli
dk
avian
precursor
ahong
human
pandem
strongli
support
possibl
reveal
precursor
also
contain
signific
highmannos
fraction
figur
interestingli
signific
oligomannos
fraction
detect
glycosit
avian
pandem
precursor
appear
quit
distinct
contemporari
avian
exampl
profil
thu
appear
highmannos
type
glycan
iav
may
well
complic
simpl
host
origin
adapt
howev
investig
reflect
avian
iav
abl
infect
human
isol
case
none
yet
fulli
evolv
properti
enabl
sustain
humantohuman
transmiss
comparison
glycom
profil
determin
addit
exampl
literatur
khatri
et
al
mirshekari
et
al
nakamura
et
al
dopheid
ward
et
al
see
figur
support
observ
certain
highmannos
glycoform
wellconserv
fulli
adapt
human
even
earli
late
exampl
togeth
data
suggest
model
iav
carri
highmannos
glycan
may
predispos
human
adapt
hostadapt
pressur
may
instead
select
strain
potenti
increas
highmannos
incorpor
exact
evolutionari
driver
unclear
sever
potenti
select
advantag
confer
shift
favor
highmannos
glycosyl
human
iav
observ
exampl
model
analys
suggest
highmannos
type
glycan
mostli
favor
close
pack
ha
surfac
glycan
conform
potenti
steric
shield
suggest
sinc
almost
glycosit
signific
oligomannos
fraction
map
function
import
region
ha
key
antigen
site
interfac
head
stem
domain
hous
membranefus
machineri
blijleven
et
al
figur
steric
block
interfac
region
high
sequenc
homolog
across
ha
subtyp
would
like
confer
advantag
human
season
iav
strain
bias
antibodi
respons
expos
area
viral
surfac
greater
toler
antigen
drift
addit
alter
present
glycoepitop
highmannos
glycan
attach
might
also
reduc
immunogen
alter
inhibit
antibodi
recognit
recess
carbohydr
compon
increas
highmannos
glycosyl
may
also
provid
replic
advantag
infect
sinc
treatment
mdck
cell
er
amannosidas
inhibitor
kifunensin
shown
lead
enhanc
growth
replic
elbein
et
al
pan
et
al
one
recent
report
suggest
effect
may
center
around
specif
induct
erassoci
protein
degrad
erad
pathway
directli
target
ha
biosynthesi
potenti
antivir
mechan
frabutt
et
al
thu
evolut
glycosit
reduc
access
nascent
glycan
mannosidas
mannosidaselik
protein
could
inhibit
pathway
lead
enhanc
replic
presenc
oligomannos
glycan
human
iav
may
also
relev
local
infect
within
respiratori
tissu
iav
infect
human
typic
initi
exposur
airborn
respiratori
droplet
result
viru
bind
receptor
surfac
epitheli
cell
upper
airway
connor
et
al
peng
et
al
shinya
et
al
well
establish
primari
innat
immun
defens
influenza
respiratori
tract
consist
secret
host
factor
includ
calciumdepend
ctype
surfact
protein
spa
spd
hartshorn
et
al
nayak
et
al
ng
et
al
notabl
spd
bind
specif
highmannos
type
nglycan
goh
et
al
particularli
man
confer
protect
pathogen
contain
oligomannos
howev
gene
express
studi
reveal
spd
mainli
isol
lung
lower
respiratori
tissu
su
et
al
thu
humanadapt
iav
primarili
target
upper
respiratori
tract
abl
increas
highmannos
nglycan
express
still
evad
host
immun
defens
potenti
biolog
rational
shift
favor
oligomannos
glycosyl
human
iav
also
interest
structur
molecular
basi
modif
aris
sinc
directli
compar
glycosit
featur
highli
divers
occup
differ
presenc
underprocess
oligomannos
rich
glycosit
influenza
ha
consist
mechan
lead
steric
graph
show
percentag
occup
specif
nlink
glycoconjug
either
complex
type
purpl
highmannos
hydrid
type
green
glycan
gray
individu
glycosit
within
aduck
precursor
hong
b
pandem
strain
bar
distribut
along
x
axi
accord
rel
posit
primari
sequenc
specif
glycosit
depict
number
glycosyl
asparagin
n
histogram
depict
averag
occup
error
bar
show
standard
error
interfer
biosynthet
process
pathway
observ
unexpect
sinc
ha
substanti
less
glycosyl
surfac
glycoprotein
numer
virus
thirti
nlink
glycan
per
monom
hiv
mer
cov
wellcharacter
exampl
compris
numer
oligomannos
site
aris
due
close
pack
mani
structur
proxim
glycosit
cao
et
al
cao
et
al
contrast
ha
glycan
far
fewer
appear
spars
arrang
figur
suggest
case
presenc
oligomannos
glycan
due
steric
restrict
impos
neighbor
glycan
chain
found
appear
glycosit
signific
highmannos
incorpor
ha
strongli
associ
global
placement
molecul
particularli
locat
within
head
domain
local
structur
andor
sequenc
adapt
serv
alter
posit
conform
attach
glycan
observ
highmannos
glycan
span
gap
protom
within
ha
trimer
notabl
figur
also
suggest
potenti
role
stabil
subunit
interact
posit
influenza
na
naga
yamaguchi
increas
oligomannos
glycoform
head
domain
human
iav
particularli
relev
season
virus
vaccin
protect
reduc
significantli
recent
year
due
substanti
antigen
drift
mismatch
egggrown
vaccin
circul
strain
regard
interest
gnl
abl
neutral
recent
virus
independ
antigen
varianc
underscor
ha
glycosyl
potenti
import
consider
futur
human
vaccin
therapeut
mab
develop
small
number
paper
report
antiha
antibodi
make
direct
contact
headdomain
glycan
barbeymartin
et
al
iba
et
al
although
plantderiv
lectin
typic
suitabl
therapeut
due
substanti
adsorpt
host
tissu
often
lead
inflammatori
side
effect
notabl
efficaci
compar
reagent
banlec
banana
lectin
swanson
et
al
swanson
et
al
griffithsin
algal
lectin
griffithsia
sp
lusvarghi
bewley
hiv
influenza
infect
latter
recent
enter
clinic
trial
nation
institut
health
certainli
provid
interest
preced
adapt
lectin
pharmaceut
applic
regard
recent
report
describ
engin
banlec
exhibit
antiinfluenza
activ
mice
extrem
well
toler
sdatson
et
al
studi
add
significantli
number
iav
sitespecif
glycom
data
avail
result
still
focu
compar
isol
exampl
clearli
substanti
investig
requir
determin
link
enhanc
highmannos
glycosyl
appar
adapt
human
host
develop
vaccin
analog
strategi
better
take
account
ha
glycosyl
statu
like
enhanc
protect
especi
within
highli
glycosyl
human
season
iav
strain
contribut
toward
goal
univers
influenza
vaccin
furthermor
gnl
also
abl
univers
label
ha
iav
sampl
glycan
microarray
provid
signific
advanc
abil
screen
receptorbind
profil
new
emerg
viru
strain
may
well
contribut
ongo
surveil
effort
detail
method
provid
onlin
version
paper
includ
follow
ulat
minim
overestim
ha
glycan
footprint
one
three
simpl
commonli
observ
glycoform
select
oligomannos
complex
model
either
man
oligomannos
man
oligomannos
asialolacnac
biantennari
glycan
complex
see
figur
structur
determin
made
sinc
previou
studi
shown
glycosit
high
oligomannos
occup
strongli
tend
toward
entir
unprocess
man
glycoform
wherea
lower
highmannos
fraction
commonli
observ
man
khatri
et
al
expect
rotam
geometri
bond
glycan
set
commonli
observ
form
gg
gt
u
respect
ndez
de
toro
et
al
wormald
et
al
conform
attach
glycan
energi
minim
use
forcefield
kirschner
et
al
deploy
within
glycoprotein
builder
final
structur
surfac
figur
assembl
pymol
dinger
llc
use
fullyglycosyl
ha
trimer
major
oligomannos
complex
glycan
color
green
purpl
respect
mix
occup
speci
shown
orang
fluoresc
intens
record
use
mapix
innopsi
glycan
microarray
experi
figur
quantifi
via
measur
mean
intens
minu
mean
background
four
median
six
total
replic
spot
data
present
averag
four
replic
standard
error
statist
analysi
appli
data
glycoproteom
experi
upload
massiv
repositori
http
massiveucsdeduproteosaf
staticmassivejsp
access
follow
link
ftp
dataset
glycan
microarray
experi
attach
supplementari
tabl
figur
accord
mirag
consortium
format
dataset
upload
public
repositori
sinc
present
resourc
exist
pdb
structur
file
glycosyl
ha
structur
gener
use
glycam
present
figur
avail
lead
contact
jame
c
paulson
jpaulson
scrippsedu
upon
request
cell
host
microb
may
